2010 AAPB Webinar 3: Part 1-Professional Conduct in Biofeedback and Neurofeedback
Presented by Donald Moss, PhD, Chair, College of Mind-Body Medicine, Saybrook University, San Francisco
No CEU's available for this recording.
Available for download after purchase
Part 1: Professional Conduct in Biofeedback and Neurofeedback, An Overview
This Recording will review legal and ethical responsibilities of biofeedback and neurofeedback practitioners. The biofeedback professional is governed in clinical practice by state regulations under the relevant licensing act, professional codes of ethics for his or her home profession, and the Professional Standards and Ethical Principles of Biofeedback (5th rev.) of the Biofeedback Certification International Alliance (BCIA). Violation of such guidelines, even when unintended, invites the risk of lawsuit, criminal prosecution, financial penalties, loss of licensure, and expensive and stressful legal and administrative reviews. The presenter will discuss relevant guidelines governing: entry level competence; scope of practice; the delivery of experimental or non-documented therapies; the informed consent process; and questions of touch, privacy, and respect. The presenter will place emphasis on the imperative to maintain a positive treatment relationship, eliciting rapport and trust. The treatment behavior, along with adherence to professional guidelines, minimizes the risk of misunderstanding and litigation.
Professionals who complete this teleseminar will be able to:
- become familiar with the Professional Standards and Ethical Principles of Biofeedback, published by BCIA, and their interpretation for decisions in biofeedback practice.
- understand how to navigate the conflicting jurisdictions of state laws and regulations, professional codes of conduct, BCIA guidelines, and federal regulations.
- review and discuss practice standards governing entry level competence and scope of practice.
- Attendees will develop an approach to educate patients about treatment options, providing cautions about potential adverse effects, and guiding patients toward an informed consent for specific therapies and treatment plan.